The global small-molecule tyrosine kinase inhibitor market is expected to grow at a significant CAGR of 7.3% during the forecast period. TKIs (tyrosine kinase inhibitors) are small molecules that block intracellular signalling pathways in tumor cells, causing deregulation of key cell functions such as proliferation and differentiation. Furthermore, small-molecule inhibitors (SMIs) are among the most effective drugs for targeted cancer therapy, according to the National Center for Biotechnology Information (NCBI). As a result, the rising prevalence of cancer is increasing demand for small molecule tyrosine kinase inhibitors, which is propelling the global small molecule tyrosine kinase inhibitor market
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/small-molecule-tyrosine-kinase-inhibitor-market
Furthermore, there were 18.1 million new cancer cases and 9.5 million cancer-related mortalities across the globe in 2020, with the number of cancer-related mortalities expected to rise to 29.5 million and 16.4 million by 2040. To stay competitive, market players are adopting various strategies such as mergers and acquisitions, geographical expansion, partnerships and collaborations, and new product launches, which contribute significantly to market growth.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
o By Type
o By Application
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape-Merck Group, Novartis AG, Pfizer Inc., Sanofi SA, GlaxoSmithKline plc.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Small Molecule Tyrosine Kinase Inhibitor Market Report Segment
By Type
- Phase1
- Phase1/2
- Phase2
- Phase2/3
- Phase3
By Application
- Lung cancer
- Breast cancer
A full report of Small Molecule Tyrosine Kinase Inhibitor Market is available at: https://www.omrglobal.com/industry-reports/small-molecule-tyrosine-kinase-inhibitor-market
Small Molecule Tyrosine Kinase Inhibitor Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Merck Group
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- GlaxoSmithKline PLC
- Biogen Idec
- Bayer Healthcare Pharmaceuticals
- Johnson & Johnson, Inc.
- Tolero Pharmaceutical
- List not Exhaustive
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
